Logo image of BRZE

BRAZE INC-A (BRZE) Stock Fundamental Analysis

NASDAQ:BRZE - Nasdaq - US10576N1028 - Common Stock - Currency: USD

39.5  -1.16 (-2.85%)

After market: 39.5 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to BRZE. BRZE was compared to 284 industry peers in the Software industry. No worries on liquidiy or solvency for BRZE as it has an excellent financial health rating, but there are worries on the profitability. BRZE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BRZE was profitable.
In the past year BRZE had a positive cash flow from operations.
BRZE had negative earnings in each of the past 5 years.
In the past 5 years BRZE reported 4 times negative operating cash flow.
BRZE Yearly Net Income VS EBIT VS OCF VS FCFBRZE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -13.64%, BRZE is doing worse than 65.58% of the companies in the same industry.
With a Return On Equity value of -25.07%, BRZE is not doing good in the industry: 60.14% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -13.64%
ROE -25.07%
ROIC N/A
ROA(3y)-15.71%
ROA(5y)-17.29%
ROE(3y)-25.19%
ROE(5y)-32.07%
ROIC(3y)N/A
ROIC(5y)N/A
BRZE Yearly ROA, ROE, ROICBRZE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

BRZE's Gross Margin of 68.64% is in line compared to the rest of the industry. BRZE outperforms 52.17% of its industry peers.
BRZE's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for BRZE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.56%
GM growth 5YN/A
BRZE Yearly Profit, Operating, Gross MarginsBRZE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

7

2. Health

2.1 Basic Checks

BRZE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BRZE has been increased compared to 1 year ago.
There is no outstanding debt for BRZE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BRZE Yearly Shares OutstandingBRZE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
BRZE Yearly Total Debt VS Total AssetsBRZE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

BRZE has an Altman-Z score of 6.22. This indicates that BRZE is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.22, BRZE is in the better half of the industry, outperforming 70.29% of the companies in the same industry.
BRZE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.22
ROIC/WACCN/A
WACC14.07%
BRZE Yearly LT Debt VS Equity VS FCFBRZE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 1.99 indicates that BRZE should not have too much problems paying its short term obligations.
BRZE's Current ratio of 1.99 is fine compared to the rest of the industry. BRZE outperforms 60.14% of its industry peers.
BRZE has a Quick Ratio of 1.99. This is a normal value and indicates that BRZE is financially healthy and should not expect problems in meeting its short term obligations.
BRZE has a Quick ratio of 1.99. This is in the better half of the industry: BRZE outperforms 60.51% of its industry peers.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.99
BRZE Yearly Current Assets VS Current LiabilitesBRZE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

BRZE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 105.56%, which is quite impressive.
The Revenue has grown by 28.30% in the past year. This is a very strong growth!
BRZE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 46.45% yearly.
EPS 1Y (TTM)105.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
Revenue 1Y (TTM)28.3%
Revenue growth 3Y46.45%
Revenue growth 5YN/A
Sales Q2Q%22.67%

3.2 Future

The Earnings Per Share is expected to grow by 49.98% on average over the next years. This is a very strong growth
BRZE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.57% yearly.
EPS Next Y143.4%
EPS Next 2Y76.57%
EPS Next 3Y61.18%
EPS Next 5Y49.98%
Revenue Next Year26.43%
Revenue Next 2Y21.6%
Revenue Next 3Y20.14%
Revenue Next 5Y18.57%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BRZE Yearly Revenue VS EstimatesBRZE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M
BRZE Yearly EPS VS EstimatesBRZE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 1975.00, the valuation of BRZE can be described as expensive.
BRZE's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of BRZE to the average of the S&P500 Index (29.63), we can say BRZE is valued expensively.
With a Price/Forward Earnings ratio of 135.93, BRZE can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BRZE is on the same level as its industry peers.
BRZE's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.68.
Industry RankSector Rank
PE 1975
Fwd PE 135.93
BRZE Price Earnings VS Forward Price EarningsBRZE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 500 1K 1.5K

4.2 Price Multiples

BRZE's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 4602.99
EV/EBITDA N/A
BRZE Per share dataBRZE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BRZE does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as BRZE's earnings are expected to grow with 61.18% in the coming years.
PEG (NY)13.77
PEG (5Y)N/A
EPS Next 2Y76.57%
EPS Next 3Y61.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BRZE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRAZE INC-A

NASDAQ:BRZE (2/21/2025, 8:04:19 PM)

After market: 39.5 0 (0%)

39.5

-1.16 (-2.85%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)12-09 2024-12-09/amc
Earnings (Next)03-24 2025-03-24/amc
Inst Owners78.73%
Inst Owner Change6.22%
Ins Owners1.03%
Ins Owner Change-16.81%
Market Cap4.09B
Analysts83.2
Price Target51.13 (29.44%)
Short Float %5.86%
Short Ratio3.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)448.89%
Min EPS beat(2)374.28%
Max EPS beat(2)523.5%
EPS beat(4)4
Avg EPS beat(4)241.85%
Min EPS beat(4)17.82%
Max EPS beat(4)523.5%
EPS beat(8)8
Avg EPS beat(8)144.84%
EPS beat(12)12
Avg EPS beat(12)102.81%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)0.77%
Min Revenue beat(2)0.59%
Max Revenue beat(2)0.95%
Revenue beat(4)4
Avg Revenue beat(4)1.31%
Min Revenue beat(4)0.59%
Max Revenue beat(4)2.83%
Revenue beat(8)8
Avg Revenue beat(8)1.83%
Revenue beat(12)12
Avg Revenue beat(12)2.49%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-13.95%
EPS NQ rev (1m)29.01%
EPS NQ rev (3m)13.08%
EPS NY rev (1m)0%
EPS NY rev (3m)55.47%
Revenue NQ rev (1m)0.28%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.74%
Valuation
Industry RankSector Rank
PE 1975
Fwd PE 135.93
P/S 7.25
P/FCF 4602.99
P/OCF 174.54
P/B 8.92
P/tB 9.59
EV/EBITDA N/A
EPS(TTM)0.02
EY0.05%
EPS(NY)0.29
Fwd EY0.74%
FCF(TTM)0.01
FCFY0.02%
OCF(TTM)0.23
OCFY0.57%
SpS5.45
BVpS4.43
TBVpS4.12
PEG (NY)13.77
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.64%
ROE -25.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.64%
FCFM 0.16%
ROA(3y)-15.71%
ROA(5y)-17.29%
ROE(3y)-25.19%
ROE(5y)-32.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.56%
GM growth 5YN/A
F-Score6
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 243.59%
Cap/Sales 3.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.99
Altman-Z 6.22
F-Score6
WACC14.07%
ROIC/WACCN/A
Cap/Depr(3y)237.11%
Cap/Depr(5y)275.44%
Cap/Sales(3y)3.12%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
EPS Next Y143.4%
EPS Next 2Y76.57%
EPS Next 3Y61.18%
EPS Next 5Y49.98%
Revenue 1Y (TTM)28.3%
Revenue growth 3Y46.45%
Revenue growth 5YN/A
Sales Q2Q%22.67%
Revenue Next Year26.43%
Revenue Next 2Y21.6%
Revenue Next 3Y20.14%
Revenue Next 5Y18.57%
EBIT growth 1Y11.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year102.3%
EBIT Next 3Y52.7%
EBIT Next 5YN/A
FCF growth 1Y101.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y149.99%
OCF growth 3YN/A
OCF growth 5YN/A